MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Regulation FD Disclosure

MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure

On January 3, 2017, MyoKardia, Inc. (the Company) issued a press
release announcing the receipt of the SOE Confirmation Notice
(the Notice) from Aventis, Inc. (Aventis), a wholly-owned
subsidiary of Sanofi S.A. (together with Aventis, Sanofi), to the
License and Collaboration Agreement dated August1, 2014 between
the Company and Aventis (the Collaboration Agreement) and Sanofis
decision to continue the Collaboration Agreement. A copy of this
press release is furnished as Exhibit 99.1 to this report on Form
8-K.

The information in this Item 7.01 and Exhibit 99.1 attached
hereto is intended to be furnished and shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such
filing.

Item8.01 Other Events.

On December30, 2016, the Company received the Notice. The Notice
serves as formal notification of Sanofis decision to continue the
research program under the Collaboration Agreement through
December31, 2018. In connection with the continuation of the
Collaboration Agreement, Sanofi is required to make a one-time,
non-refundable, non-creditable cash payment to the Company of
$45.0 million by January31, 2017.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit

No.

Description

99.1 Press Release issued by MyoKardia, Inc. on January 3, 2017,
furnished herewith


About MYOKARDIA, INC. (NASDAQ:MYOK)

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.

MYOKARDIA, INC. (NASDAQ:MYOK) Recent Trading Information

MYOKARDIA, INC. (NASDAQ:MYOK) closed its last trading session 00.00 at 12.95 with 91,530 shares trading hands.

An ad to help with our costs